# Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

> **NCT05918328** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 610 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Albumin paclitaxel+trastuzumab+pyrrolitinib
- **DRUG:** Docetaxel+Carboplatin+trastuzumab+Parstuzumab

## Key facts

- **NCT ID:** NCT05918328
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-03
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 610 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918328, "Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05918328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*